Nadia Zaffaroni Selected Research

namitecan

2/2014	Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
7/2012	The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nadia Zaffaroni Research Topics

Disease

131	Neoplasms (Cancer) 05/2024 - 04/2002
39	Prostatic Neoplasms (Prostate Cancer) 07/2022 - 02/2003
21	Carcinoma (Carcinomatosis) 04/2022 - 09/2002
17	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2013
16	Breast Neoplasms (Breast Cancer) 03/2023 - 09/2002
15	Melanoma (Melanoma, Malignant) 01/2023 - 01/2002
14	Sarcoma (Soft Tissue Sarcoma) 05/2024 - 09/2002
14	Mesothelioma 10/2022 - 01/2007
6	Ovarian Neoplasms (Ovarian Cancer) 11/2021 - 09/2005
5	Lung Neoplasms (Lung Cancer) 11/2022 - 12/2002
5	Triple Negative Breast Neoplasms 05/2021 - 03/2011
4	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 01/2019
4	Disease Progression 12/2021 - 01/2007
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 12/2002
3	Rhabdoid Tumor (Rhabdoid Tumors) 05/2024 - 12/2023
3	Synovial Sarcoma (Synovioma) 12/2021 - 01/2018
3	medullary Thyroid cancer 08/2016 - 10/2011
3	Experimental Melanoma 01/2016 - 07/2013
3	Lymphoma (Lymphomas) 01/2016 - 11/2014
3	Colonic Neoplasms (Colon Cancer) 10/2010 - 06/2007
2	Malignant Mesothelioma 04/2023 - 01/2020
2	Desmoplastic Small Round Cell Tumor 04/2023 - 01/2023
2	Stomach Neoplasms (Stomach Cancer) 01/2023 - 10/2007
2	Infections 01/2023 - 01/2004
2	Osteosarcoma (Osteogenic Sarcoma) 11/2022 - 05/2013
2	Carcinogenesis 12/2021 - 04/2020
2	Liposarcoma 03/2021 - 06/2008

Drug/Important Bio-Agent (IBA)

23	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2022 - 09/2002
23	MicroRNAs (MicroRNA)IBA 10/2022 - 03/2009
19	SurvivinIBA 05/2021 - 01/2002
17	Antineoplastic Agents (Antineoplastics)IBA 01/2023 - 04/2005
16	Proteins (Proteins, Gene)FDA Link 07/2022 - 04/2005
15	Cisplatin (Platino)FDA LinkGeneric 11/2021 - 01/2002
9	Biomarkers (Surrogate Marker)IBA 02/2024 - 07/2009
9	Estrogen ReceptorsIBA 12/2022 - 07/2003
9	Drug CombinationsIBA 10/2021 - 08/2012
8	Phosphotransferases (Kinase)IBA 05/2024 - 10/2010
8	LigandsIBA 10/2021 - 08/2012
8	PlatinumIBA 10/2021 - 08/2012
8	Catalytic RNA (Ribozymes)IBA 01/2007 - 01/2002
7	EnzymesIBA 12/2022 - 02/2003
7	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 04/2009
7	AndrogensIBA 10/2018 - 02/2003
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 07/2003
6	Histone Deacetylase InhibitorsIBA 12/2021 - 08/2012
5	heparanaseIBA 12/2021 - 07/2016
5	Androgen Receptors (Androgen Receptor)IBA 09/2019 - 09/2014
5	CPG-oligonucleotideIBA 01/2016 - 10/2011
5	Small Interfering RNA (siRNA)IBA 07/2015 - 01/2006
4	tazemetostatIBA 05/2024 - 04/2021
4	Irinotecan (Camptosar)FDA LinkGeneric 04/2023 - 05/2013
4	Estrogens (Estrogen)FDA Link 12/2022 - 07/2003
4	selinexorIBA 05/2021 - 10/2014
4	naphthalenediimideIBA 10/2019 - 01/2015
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 09/2005
4	tyrosine receptor (receptor, tyrosine)IBA 07/2016 - 10/2010
4	Caspase 3 (Caspase-3)IBA 01/2016 - 09/2005
4	Messenger RNA (mRNA)IBA 01/2016 - 07/2004
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023 - 03/2014
3	AnthracyclinesIBA 01/2023 - 10/2011
3	pazopanib FDA Link 01/2023 - 08/2012
3	Aromatase (CYP19)IBA 12/2022 - 04/2019
3	LipidsIBA 04/2022 - 10/2011
3	Peptides (Polypeptides)IBA 10/2021 - 07/2015
3	Gemcitabine FDA Link 09/2020 - 01/2018
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 06/2014
3	Heparitin Sulfate (Heparan Sulfate)IBA 01/2018 - 07/2016
3	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 01/2018 - 11/2016
3	Platinum Compounds (Compounds, Platinum)IBA 11/2016 - 02/2003
3	OligodeoxyribonucleotidesIBA 01/2016 - 01/2013
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 10/2010
3	Poly I-CIBA 01/2016 - 01/2013
3	CytokinesIBA 01/2016 - 01/2014
3	OligonucleotidesIBA 10/2015 - 01/2004
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 03/2015 - 05/2003
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 07/2012 - 08/2011
3	indole-3-carbinolIBA 01/2012 - 07/2003
3	Hormones (Hormone)IBA 01/2012 - 02/2003
2	Lactate Dehydrogenase 5IBA 04/2023 - 01/2020
2	TrabectedinIBA 04/2023 - 01/2023
2	IronIBA 01/2023 - 01/2022
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2023 - 04/2017
2	Glycoside Hydrolases (Endoglycosidases)IBA 12/2021 - 11/2016
2	Bispecific AntibodiesIBA 10/2020 - 01/2019
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 06/2012
2	naphthaleneIBA 10/2019 - 01/2015
2	Nucleic AcidsIBA 10/2019 - 07/2015
2	AntigensIBA 01/2019 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2019 - 01/2013
2	enzalutamideIBA 10/2018 - 09/2014
2	Heparin (Liquaemin)FDA LinkGeneric 01/2018 - 07/2016
2	TubulinIBA 08/2016 - 01/2011
2	Propidium (Propidium Iodide)IBA 01/2016 - 03/2011

Therapy/Procedure

46	Therapeutics 05/2024 - 04/2003
12	Drug Therapy (Chemotherapy) 01/2023 - 07/2004
7	Radiotherapy 01/2023 - 08/2009
6	Castration 01/2022 - 02/2014
3	Precision Medicine 01/2021 - 03/2010
3	Immunotherapy 10/2020 - 01/2016
2	Neoadjuvant Therapy 01/2018 - 07/2003